Although clinical resistance is a relatively rare event (in up to 20% of cases), many mechanisms including mutation of BCR-ABL1, especially of the ATP binding pocket [6] or activation of additional signaling pathways independent of BCR-ABL1have been identified in CML [5, 10]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.